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BACKGROUND: Early-life exposure to lead is associated with deficits in neurodevelopment and with hematopoietic system toxicity. DNA methylation
may be one of the underlying mechanisms for the adverse effects of prenatal lead on the offspring, but epigenome-wide methylation data for low lev-
els of prenatal lead exposure are lacking.
OBJECTIVES:We investigated the association between prenatal maternal lead exposure and epigenome-wide DNA methylation in umbilical cord blood
nucleated cells in Project Viva, a prospective U.S.-based prebirth cohort with relatively low levels of lead exposure.
METHODS: Among 268 mother–infant pairs, we measured lead concentrations in red blood cells (RBC) from prenatal maternal blood samples, and
using HumanMethylation450 Bead Chips, we measured genome-wide methylation levels at 482,397 CpG loci in umbilical cord blood and
retained 394,460 loci after quality control. After adjustment for batch effects, cell types, and covariates, we used robust linear regression models
to examine associations of prenatal lead exposure with DNA methylation in cord blood at epigenome-wide significance level [false discovery
rate ðFDRÞ<0:05].
RESULTS: The mean [standard deviation (SD)] maternal RBC lead level was 1.22 (0.63) lg=dL. CpG cg10773601 showed an epigenome-wide signifi-
cant negative association with prenatal lead exposure (−1:4% per doubling increase in lead exposure; p=2:3× 10−7) and was annotated to C-Type
Lectin Domain Family 11, Member A (CLEC11A), which functions as a growth factor for primitive hematopoietic progenitor cells. In sex-specific
analyses, we identified more CpGs with FDR<0:05 among female infants (n=38) than among male infants (n=2). One CpG (cg24637308), which
showed a strong negative association with prenatal lead exposure among female infants (−4:3% per doubling increase in lead exposure;
p=1:1× 10−06), was annotated to Dynein Heavy Chain Domain 1 gene (DNHD1) which is highly expressed in human brain. Interestingly, there were
strong correlations between blood and brain methylation for CpG (cg24637308) based on another independent set of samples with a high proportion
of female participants.
CONCLUSION: Prenatal low-level lead exposure was associated with newborn DNA methylation, particularly in female infants. https://doi.org/
10.1289/EHP1246
Introduction
Lead is an environmental pollutant whose widespread use has
caused extensive environmental contamination and health effects
throughout the world (WHO 2015). Lead affects multiple body
systems, and there is no known level of lead exposure that is con-
sidered safe (WHO 2015). Lead can pass freely across the pla-
centa (Chuang et al. 2001), and as a result, there is substantial
concern about the potential adverse effects of prenatal lead
exposure on the developing fetus. Fetal and early-life exposure
to lead, even at low levels, has been associated with a range of
adverse health outcomes, including preterm delivery and small-
for-gestational-age birth (Jelliffe-Pawlowski et al. 2006; Perkins
et al. 2014), poor growth in childhood (Afeiche et al. 2011),
impaired cognitive and behavioral functions (Boucher et al. 2014;
Liu et al. 2014; Virgolini et al. 2008), and hematopoietic system
toxicity (Jacob et al. 2000; Serrani et al. 1997). Interestingly, sex
differences in lead exposure–related health effects have been
reported in previous studies (Afeiche et al. 2011; Bunn et al.
2001; Perkins et al. 2014; Schneider et al. 2013; Virgolini et al.
2008), suggesting sexually dimorphic responses to lead exposure
between males and females.
Previous animal, in vitro, and epidemiological studies have
suggested that DNA methylation may be one of the mechanisms
by which lead exposure exerts its biological effects. For example,
lead exposure induced dose- and sex-specific responses in DNA
methylation at several specific loci that were responsible for phe-
notypes including weight and coat color in mice (Faulk et al.
2013). An in vitro study showed that lead exposure reduces the
global DNA methylation level by noncompetitive inhibition and
alteration of DNA methyltransferase (DNMT) expression (Sanchez
et al. 2017), whereas additional animal studies also found that
lead exposure affects the expression of maintenance enzyme
DNMT1 and the de novo methyltransferase DNMT3a in the brain
(Schneider et al. 2012; Schneider et al. 2013). Specifically, an
in vitro study demonstrated that lead exposure induced changes
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in the methylation status of genes involved in neurogenetic sig-
naling pathways in human embryonic stem cells and altered their
neuronal differentiation (Senut et al. 2014). These studies provide
evidence that lead exposure may affect both global and brain
genomic methylation. In addition, a recent epidemiological study
found that the epigenome-wide DNA methylation profile in um-
bilical cord blood was associated with high levels of prenatal
lead exposure in 127 mother–infant pairs in lead-endemic regions
outside the United States (Engström et al. 2015).
Although existing evidence supports the role of lead exposure
in modifying DNA methylation, little is known about potential
effects of relatively low levels of lead exposure in utero—com-
mon to much of the U.S. population—on DNA methylation. It is
also unknown whether variation in DNA methylation associated
with prenatal lead exposure may last over time, which may help
elucidate the long-term health effects of lead exposure. We aimed
to investigate these questions by performing an epigenome-wide
association study (EWAS) of low-level maternal lead exposure
[<5 lg=dL in red blood cells (RBC)] and DNA methylation pro-
files in umbilical cord blood samples from 268 mother–infant
pairs enrolled in Project Viva, a U.S.-based prebirth cohort, over-
all and separately among boys and girls. We also attempted to
replicate the observed prenatal lead exposure–cord blood DNA
methylation associations using data collected during midchild-
hood for 240 children (7–10 y of age).
Methods
Study Subjects
Study subjects were mother–infant pairs in Project Viva, a pro-
spective prebirth cohort with 2,128 women recruited between
1999 and 2002 from Atrius Harvard Vanguard Medical Associates
in eastern Massachusetts. Eligibility criteria included English
speaking, singleton pregnancy, and <22 wk of gestation. All
women provided written informed consent, and the research was
approved by the Institutional Review Board at Harvard Pilgrim
Health Care.
We collected blood samples from 1,614 women at an average
of 27.9 wk of gestation and analyzed blood samples for 952
women for lead, selecting those with children who participated in
follow-up visits in midchildhood. We measured genome-wide
DNA methylation using the Infinium HumanMethylation450
(HM450K) BeadChip (Illumina, Inc.) for 507 umbilical cord
blood samples collected at delivery and 473 child blood samples
collected during midchildhood. A total of 485 cord blood samples
and 460 midchildhood blood samples passed quality-control
(QC) procedures (see Table S1). Among these, 269 samples had
data on both maternal RBC lead and DNA methylation in
cord blood, and 241 samples had data on both maternal RBC
lead and DNA methylation in midchildhood blood samples. We
excluded one sample with undetectable maternal RBC lead, leav-
ing 268 cord blood samples and 240 midchildhood blood sam-
ples for the data analysis. Participants with cord blood samples
and midchildhood blood samples (n=377, with 131 overlapped
between delivery and midchildhood) were generally similar in
baseline characteristics compared with those who were not
included (n=1,751, data not shown). However, women included
in this analysis were more likely to be white (76% vs. 65%) and
to have a college degree (70% vs. 64%) than those who were
excluded.
Sample Collection
All blood samples were collected in vacutainer tubes containing
ethylenediaminetetraacetic acid (EDTA) and were put on ice
immediately. The tubes were centrifuged at 1,700× g for 10 min
at 4°C to separate plasma, nucleated cells (including leukocytes
and nucleated RBC in cord blood and leukocytes in maternal
blood), and RBC within 24 h after collection. We extracted
genomic DNA from the nucleated cells with commercially avail-
able PureGene Kits (Fisher, Catalog Nos. A407-4, A416-4;
Qiagen, Catalog Nos.158908, 158912, 158924). Sample aliquots
were then stored at −80C until analysis.
Measurement of RBC Lead
Lead concentrations in RBC from prenatal blood samples were
measured at the Trace Metals Laboratory at Harvard T.H. Chan
School of Public Health in Boston, Massachusetts. RBC samples
were weighed and digested for 24 h in 2 mL of concentrated nitric
acid and 1 mL of 30% hydrogen peroxide per 1 g of RBC.
Samples were then diluted to a volume of 10 mL with deionized
water and were measured using a dynamic reaction cell–inductively
coupled plasma mass spectrometer (Elan DRC II; PerkinElmer)
for lead concentrations. Quality-control measures included analy-
sis of initial and continuous calibration verification standards, 1-ppb
lead standard, procedural blanks, QC standard [National Institute of
Standards and Technology Standard Reference Material (NIST
SRM) 1643d, Trace Elements in Water (NIST SRM955b, Lead in
Blood)]. Results were calculated as the mean of five replicate meas-
urements. The limit of detection for this procedure was 0:2 ng=mL
in RBC.
Epigenome-Wide DNAMethylation Profiling and
Quality Controls
Extracted DNA underwent bisulfite modification using the Zymo
EZ DNAMethylation kit (Zymo Research). We randomized sam-
ples of bisulfite-modified DNA (1 lg for each sample) across dif-
ferent plates and BeadChips to ensure balance by sex and to
reduce the influence of batch effects. Epigenome-wide DNA
methylation analysis using the HM450K microarray interrogates
482,397 methylation loci at single-nucleotide resolution. The
microarray measurements were processed at Illumina, Inc. We
preprocessed data using the minfi package in R software (R
Project for Statistical Computing). We excluded samples if they
a) were replicates; b) were of low quality with individual call rate
<0:98; c) had genotype mismatch; or d) had sex mismatch (see
Table S1). We excluded methylation probes if a) they were on ei-
ther the X or the Y chromosome; b) they were nonCpG probes;
c) they had nonsignificant detection p-values (p>0:05) for >1%
of the samples; d) they had been identified as cross-hybridizing
with other genomic locations (Chen et al. 2013); or e) single nu-
cleotide polymorphism (SNP)-associated probes at either the sin-
gle base extension or within the target region for SNPs that have
a minor allele frequency (MAF) ≥0:05. A total of 394,460 auto-
somal probes passed the QC. We performed background correc-
tion and dye-bias equalization using the normal-exponential
out-of-band (noob) correction method (Triche et al. 2013). We
performed a probe type normalization using the beta-mixture
quantile (BMIQ) method in the minfi package in R (Teschendorff
et al. 2013).
Covariates
We collected maternal demographics including age, race/ethnic-
ity, educational level, parity history, and pregnancy health infor-
mation including smoking status and prepregnancy weight and
height, as well as infant sex using self-administered question-
naires and interviews during pregnancy. We collected informa-
tion on delivery date from medical records. Prepregnancy body
mass index (BMI; kilograms per square meter) was calculated
Environmental Health Perspectives 087019-2
from self-reported prepregnancy weight and height. Women
reported their last menstrual period (LMP) at enrollment, and
we calculated gestational age by subtracting the LMP date from
the delivery date or by ultrasound when available and when it
differed from the LMP by more than 10 d (Gillman et al. 2004).
To estimate cell-type distribution in blood samples, we used a
reference panel of nucleated cells (leukocytes and nucleated
RBC) isolated from cord blood (Bakulski et al. 2016) for cord
blood samples and an adult leukocyte reference panel for blood
samples collected in midchildhood as implemented in minfi
(Aryee et al. 2014; Reinius et al. 2012). Leukocytes included
CD8+ T cells, CD4+ T cells, natural killer (NK) cells, mono-
cytes, and B cells.
Statistical Analysis
We accounted for batch effects from plates and for other potential
sources of technical variability in the noob-adjusted and BMIQ-
normalized cord blood methylation data using the ComBat
adjustment (Johnson et al. 2007). We visually inspected the effec-
tiveness of the removal of batch effects using principal compo-
nent analysis before and after technical batch adjustment.
ComBat-adjusted cord blood methylation b-values were log2-
transformed to M-values to be more appropriate for differential
analysis of DNA methylation (Du et al. 2010). Robust linear
regression models were constructed using the MASS package in
R, with M-values included as dependent variables and log2-
transformed maternal RBC lead levels as the main predictor,
with adjustment for other potential confounders. Covariates
included child sex, gestational age (weeks; as a continuous
variable), maternal prepregnancy BMI (kilograms per square
meter; as a continuous variable), age at enrollment (years; as a
continuous variable), parity history (nulliparous, nonnullipar-
ous), educational level (college graduate, noncollege graduate),
smoking status during pregnancy (never, former, current
smoker), race (white, nonwhite), and blood cell type distribu-
tion in cord blood.
To account for multiple testing, we only report top loci with a
false discovery rate (FDR)-corrected p-value< 0:05, as has com-
monly been implemented in previous EWAS analyses (Engström
et al. 2015; Senut et al. 2014). To facilitate interpretation of the
results, we report effect estimates in the main text using the
b-value scale for top loci with an FDR< 0:05 based on the ro-
bust linear regression. We further stratified the EWAS by child
sex, using the same criterion of FDR< 0:05 to determine the
top loci. We tested the interaction between child sex and lead
by adding a multiplicative term in the model along with their
main effect terms for all significant loci meeting the criterion
FDR< 0:05.
We attempted to replicate the identified associations for top
loci in cord blood by further examining associations of prenatal
lead exposure with DNA methylation at the same top CpGs in
midchildhood blood samples. For these analyses, we again per-
formed robust linear regression analyses with adjustment for the
same covariates [but using Houseman blood cell type algorithms
based on an adult blood cell reference panel (Aryee et al. 2014;
Reinius et al. 2012)] as well as for child age at blood sample col-
lection. We drew visualized regional DNA comethylation pat-
terns for identified potential target genes using the coMET
package in R. To address the potential residual confounding due
to smoking, we first performed sensitivity analyses excluding
infants with sustained maternal smoking during pregnancy
(n=7) according to a definition reported elsewhere (Joubert et al.
2016). We further created a methylation score predicting smok-
ing status by calculating the linear combination of methylation
values of 28 CpGs as described elsewhere (Reese et al. 2017),
and we adjusted for the score as a quartile-covariate instead of
adjusting for the smoking status in the EWAS analyses. Finally,
we used the bumphunter package from Bioconductor to perform
a bumphunting analysis, as previously described (Jaffe et al.
2012), to detect any differentially methylated regions (DMRs)
relative to prenatal maternal lead exposure. Briefly, we fit models
with adjustment for the same covariates as in the primary EWAS
analyses and ran bumphunter on the b-values using log2-
transformed RBC-lead as the exposure of interest. All statistical
analyses were performed using R 3.2.3 (R Project for Statistical
Computing).
Results
Among the 268 mothers included in the primary analysis, 138
(51.5%) had female infants (Table 1). The mean age of women at
enrollment was 31.9 y; 51.1% were nulliparous, 79% were white,
and 69.0% were college graduates. The mean maternal RBC
blood lead level was 1:22 lg=dL [standard deviation (SD), 0.63;
range, 0.29–4.97] and was generally similar between mothers of
female (1:24 lg=dL) and male (1:19 lg=dL) infants (Wilcoxon
rank test p=0:30, see Table S2). This level approximates to a
whole-blood level of 0:50 lg=dL based on the estimate that RBC
concentrations are the products of the whole-blood level divided by
hematocrit (∼ 40% in women) (Chuang et al. 2001). Characteristics
of the 240 mother–child pairs with child blood samples in midchild-
hood were largely similar. The mean age of children in midchild-
hood was 7.9 y (SD, 0.8; range, 7–10).
Our analysis showed that the p-value distribution of all CpGs
was generally similar to the theoretical distribution among all
newborns and female infants (in quantile–quantile plots, k values
were 0.9308 and 1.0192, respectively) and was slightly different
from the theoretical distribution among male infants (k=0:7967;
see Figure S1). We found that methylation levels at four CpGs
demonstrated significant negative associations (FDR< 0:05)
with maternal RBC lead among all newborns (Table 2; see also
Figure S2A). Among these CpGs, one (cg10773601) was anno-
tated to <1,500 bps from the transcription start site of C-Type
Lectin Domain Family 11, Member A (CLEC11A). For each dou-
bling increase in maternal RBC lead levels, there was a 1.4%
decrease in the methylation level of cg10773601 in cord blood
(p= 2:3× 10−07). This association appeared to be linear over the
lead exposure range (Figure 1A). This effect estimate attenuated
to −0:5% in midchildhood blood samples (p=0:12; see Table
S3). Effect estimates for the other three loci in cord blood and
Table 1. Characteristics of Project Viva mother–infant pairs with umbilical
cord blood and midchildhood blood methylation measurement.
Characteristic
Birth
(n=268)
Midchildhood
(n=240)
Maternal
Prepregnancy BMI, kg=m2: Mean (SD) 24.2 (5.0) 24.5 (4.9)
Age at enrollment, years: Mean (SD) 31.9 (4.7) 32.1 (5.3)
Nulliparous: n (%) 131 (48.9) 113 (47.1)
College graduate: n (%) 185 (69.0) 169 (70.4)
Smoking status: n (%)
Never 178 (66.4) 168 (70.0)
Former 55 (20.5) 47 (19.6)
During pregnancy 35 (13.1) 25 (10.4)
Maternal white race/ethnicity: n (%) 212 (79.1) 173 (72.1)
2nd-trimester Pb, lg=dL: Mean (SD) 1.22 (0.63) 1.20 (0.53)
Child
Female: n (%) 138 (51.5) 121 (50.4)
Gestational age at birth, wk: Mean (SD) 39.7 (1.6) 39.5 (1.7)
Age at blood collection, years:Mean (SD) – 7.9 (0.8)
Note: BMI, body mass index; Pb, lead; SD, standard deviation.
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midchildhood blood samples were generally minimal and were
not annotated to any genes.
We identified somewhat different top loci in sex-specific
EWAS analyses, and most of the loci had p values< 0:05 for
interaction tests between infant sex and lead exposure (Table 2).
Among male infants, methylation levels at only two CpGs in
cord blood showed significant but small positive associations
with maternal RBC lead at FDR< 0:05 (Table 2; see also Figure
S2B). Neither of these two CpGs showed an association with pre-
natal lead in blood DNA collected in midchildhood (see Table
S3). Among female infants, maternal RBC lead levels were nega-
tively associated with methylation levels of 29 CpGs and were
positively associated with DNA methylation at 9 CpGs in cord
blood at FDR< 0:05 (Table 2; see also Figure S2C). One CpG
(cg24637308) showed a strong negative association with prenatal
lead exposure (the effect estimate was −4:3% for each doubling
of maternal RBC lead, p=1:1× 10−06). This association also
appeared to be linear over the lead exposure range (Figure 1C)
and was consistent in midchildhood, with each doubling of
maternal RBC lead associated with 4.1% lower methylation in
midchildhood females (p=0:003). The CpG cg24637308 is
located in the body of the Dynein Heavy Chain Domain 1 gene
(DNHD1) and is annotated to a CpG island). Effect estimates for
the other loci among female infants were either minor or were
substantially attenuated in midchildhood. Visualization of re-
gional DNA comethylation patterns for top loci showed that most
CpGs around the DNHD1 gene had similar changes in the same
direction as that of the top CpG cg24637308 in association with
lead exposure, although they did not pass the FDR adjustment
(Figure 2). Lists of annotated CpGs with uncorrected p<0:05 in
EWAS analyses and scatterplots for prenatal RBC lead levels and
methylation levels at top loci other than cg10773601 and
cg24637308 as shown in Table 2 for all newborns, male infants,
and female infants have been included in the Supplemental
Material for reference (see Tables S4–S6; see also Figure S3).
Sensitivity analyses excluding infants with sustained maternal
smoking yielded generally similar results (see Tables S7–S9).
Results from analyses with adjustment for the methylation score
predicting smoking status were also generally consistent with the
original results, and major top CpGs, including cg10773601 and
cg24637308, still met FDR< 0:05 (see Tables S10–S12).
Because DNA methylation is tissue-specific, we were inter-
ested in examining the consistency of methylation patterns
between our surrogate tissue (blood) and the potential target tis-
sue (e.g., brain). We therefore investigated blood–brain DNA
methylation correlations for top loci based on an independent
sample dominated by adult females (the female:male ratio was
approximately 2:1) (Hannon et al. 2015) and found that blood
DNA methylation at the cg24637308 locus (DNHD1) was
highly correlated with methylation at the same locus in the pre-
frontal cortex (r=0:77), the entorhinal cortex (r=0:78), the
superior temporal gyrus (r=0:75) and the cerebellum (r=0:63)
(Figure 3).
We also investigated the top loci identified by a previous
EWAS analysis on prenatal lead exposure and cord blood DNA
methylation (Engström et al. 2015) based on our data set and
found that one of the loci (cg05374025) was significantly associ-
ated with prenatal lead exposure in our samples (p=0:031; see
Table S13).
Bumphunting analysis identified only one small DMR with
two CpGs in chromosome 13 (chr13: 50194554–50194643) asso-
ciated with RBC lead for all newborns [family-wise error rate
ðFWERÞ<0:05) and two DMRs in chromosome 6 (chr6:
29648271–29649084) and chromosome 5 (chr5: 135415819–
135416613) for male infants (FWER< 0:05; see Table S14).Ta
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However, these regions did not contain any of the top loci
reported in Table 2.
Discussion
In this study of 268 U.S. mother–infant pairs, we found that pre-
natal RBC lead levels were associated with differential DNA
methylation levels at several CpGs in umbilical cord blood. We
also observed notable sex differences: RBC lead levels were asso-
ciated with DNA methylation in more CpGs in female infants
than in male infants. Most of the identified CpGs showed lower
methylation levels in association with higher prenatal lead expo-
sure. Estimated whole blood lead levels in our sample
(0:50 lg=dL) were slightly below the U.S. national average for
women (0:60 lg=dL) (Jones et al. 2010). Our results suggest that
even at very low levels, prenatal lead exposure may be signifi-
cantly associated with altered DNA methylation profiles in
newborns.
Lead is a multiple-source pollutant well known for its adverse
effects, and the main target organs of lead are the hematopoietic,
nervous, and renal systems (Papanikolaou et al. 2005).
Interestingly, we found that in utero lead exposure was associated
with altered methylation levels at CpGs located within or near
important regulatory genes of hematopoietic and nervous func-
tions (i.e., CLEC11A and DNHD1). Lead is well known to inter-
fere with hemoglobin synthesis and to affect erythrocyte
morphology and survival (Sun et al. 2012). The gene CLEC11A
encodes a secreted sulfated glycoprotein (CLEC11A) that func-
tions as a growth factor for primitive hematopoietic progenitor
cells (Mio et al. 1998). CLEC11A stimulates the proliferation
and differentiation of hematopoietic precursor cells from various
lineages, including RBCs, lymphocytes, granulocytes, and mac-
rophages (Hiraoka et al. 2001).
DNHD1 (DYNC1H1) is a member of the dynein heavy chain
family and is highly expressed in the brain. Cytoplasmic dynein
complex comprises subunits assembled on the DNHD1 dimer
and is particularly important for neurons because it carries essen-
tial signals and organelles from distal sites to the cell body
(Schiavo et al. 2013). Our results on DNHD1 suggest that meth-
ylation changes in this gene may be potential targets of in utero
lead exposure. Interestingly, there were strong correlations
between blood–brain methylation for cg24637308 (DNHD1)
based on another independent set of samples with a high propor-
tion of female participants (Hannon et al. 2015). Furthermore, the
significant inverse association among female infants seemed con-
sistent through midchildhood, highlighting the possibility of
long-term programming effects of lead exposure. In support of
our findings, previous studies have documented a strong link
between lead exposure and impaired cognitive and behavioral
functions (Boucher et al. 2014; Liu et al. 2014; Virgolini et al.
2008).
Our study found substantial sex differences in lead exposure–
associated methylation changes. It is plausible that the slightly
higher RBC levels in mothers of female infants than in male
infants may be partially responsible for the more significant
CpGs found in female infants in the study, although the differ-
ence in exposure levels did not reach statistical significance.
Similarly, our previous study on prenatal maternal lead and birth
outcomes and another epidemiological study on prenatal lead and
childhood body weight also did not find appreciable differences
Figure 1. Scatterplots for prenatal red blood cell lead levels and cg10773601 (left panel) and cg24637308 (right panel) methylation levels of umbilical cord
blood DNA among all newborns (A), male infants (B), and female infants (C).
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in lead exposure levels between the sexes despite the presence of
different effect estimates associated with lead exposure in males
and females (Afeiche et al. 2011; Perkins et al. 2014). In light of
the fact that several toxicological studies also observed appreci-
able effect differences between the sexes at the same doses of
lead exposure (Bunn et al. 2001; Virgolini et al. 2008), it is possi-
ble that the variation in the lead-associated effect spectrum over
the sexes may be associated with sex-specific biological mecha-
nisms rather than with the lead exposure doses. In addition, it has
been shown that sex does influence genomic methylation status
(Liu et al. 2010), yet little is known about sex differences in the
regulation of the epigenome. Interestingly, a previous animal
study found that the effects of lead exposure on DNMTs and
DNA-binding proteins in the hippocampus appear to be different
Figure 2. Visualization of regional DNA comethylation patterns for genes CLEC11A (A) and DNHD1 (B) in umbilical cord blood among all newborns. Black
dots indicate the identified key loci (cg10773601 and cg24637308), blue dots indicate CpGs in the same direction, and red dots indicate CpGs in the opposite
direction associated with lead exposure.
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in males and females and are further differentiated by the period
of development during which exposure occurs (Schneider et al.
2013). The authors hypothesized that an interaction between
genes and sex hormones during development, modified by lead
exposure, may make specific brain regions such as the hippocam-
pus differentially susceptible to methylation-associated modula-
tion of transcriptional regulation. It is possible that the potential
effects of lead exposure on epigenetic mechanisms, as observed
in previous studies and in the present study, may contribute to a
differential susceptibility between males and females to the
adverse health outcomes reported in previous epidemiological
and toxicological studies (Afeiche et al. 2011; Bunn et al. 2001;
Perkins et al. 2014; Virgolini et al. 2008).
A previous study also investigated the epigenome-wide
association of prenatal lead exposure with cord blood DNA meth-
ylation profiles in a birth cohort in rural Bangladesh (n=127)
with high environmental lead levels, and the authors identified a
set of loci with FDR< 0:05, among which some were located
around the gene glycoprotein VI (GP6) (Engström et al. 2015).
However, only one of these loci (cg05374025) reached statistical
significance in our samples. It is notable that prenatal lead expo-
sure levels were much higher in the Bangladesh cohort (mean
maternal RBC lead level, 94 lg=kg) than in our U.S. samples
(mean maternal RBC lead level, 1:22 lg=dL  12 lg=kg). In
addition, several important participant characteristics differed
substantially between the two study populations, including ethnic
background and BMI (the median maternal BMI was 20 kg=m2
in the Bangladesh cohort and 23 kg=m2 in our cohort). Therefore,
the potential adverse effect spectra and the action patterns of pre-
natal lead exposure may vary substantially between these two
cohorts.
Our study has several strengths. We were able to prospec-
tively investigate the methylation changes in association with
prenatal lead exposure among male infants and female infants
separately. We collected both cord blood samples and midchild-
hood blood samples, allowing us to examine the consistency of
in utero lead exposure–DNA methylation associations over time.
In addition, we were able to control for a number of covariates
based on the detailed cohort follow-up information.
Our study also has several limitations. First, the distribution
of lead exposure was relatively narrow, and the exposure levels
were quite low. However, this range gave us the opportunity to
investigate the potential effects of very low-level exposure, which
represents common exposure levels in the United States and in
other Western countries. Our results may not be generalizable to
populations with different exposure ranges, or to lower-income
and racial/ethnic minority populations. Second, our study meas-
ured maternal lead in RBC instead of in whole blood.
Nevertheless, this is likely to be an accurate biomarker because
99% of whole-blood lead is found in RBC; thus, RBC lead is
very highly correlated with whole-blood concentrations (Leggett
1993). Third, although lead is known to affect multiple organs,
DNA methylation was measured using unfractionated blood col-
lected at delivery and midchildhood—the only available biologi-
cal sample. Whether the associations reported herein may reflect
associations between in utero lead exposure and methylation at
target organs is uncertain. However, peripheral blood is the major
carrier of lead absorbed into the human body, and peripheral
blood cells contact and react directly with the internal forms of
lead (Chiesa et al. 2006). Furthermore, there are strong correla-
tions between blood and brain methylation for the CpG
cg24637308 on the body of the DNHD1 gene, suggesting that pe-
ripheral blood may serve well as a surrogate tissue for the target
organ brain for certain key regulatory loci. Fourth, we were
unable to investigate the exact biological mechanisms behind the
observed methylation changes associated with prenatal lead ex-
posure. Although lead exposure has been found to reduce the
global DNA methylation level by noncompetitive inhibition and
alteration of DNMT (Sanchez et al. 2017), this would not explain
why not all affected genes are in the negative direction. Further
studies are needed to investigate this issue in detail. Fifth, we
were unable to validate the methylation changes associated with
Figure 3. Scatterplots and correlations for cg24637308 (DNHD1 gene) methylation levels of blood DNA and four brain regions: prefrontal cortex (PC, n=74),
entorhinal cortex (EC, n=71), superior temporal gyrus (STG, n=75), and cerebellum (CE, n=71), based on an independent data set dominated by females
(the female:male ratio was approximately 2:1) from (Hannon et al. 2015).
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lead exposure using another method, such as gene expression
assays or pyrosequencing assays, owing to the unavailability of
extra biological samples. Nevertheless, the visualization of re-
gional DNA comethylation patterns for potential target genes
reveals generally consistent change patterns for CpGs in these
genes, strengthening the validity of the reported results. Finally,
we aimed to examine the potential effects of in utero lead expo-
sure and did not include lead exposures after birth and before
midchildhood; whether the associations between prenatal lead ex-
posure and methylation in midchildhood may be confounded by
other exposures is unknown. However, early pregnancy is a criti-
cal time window for epigenetic programming in the fetus, and it
is during this time period that adverse in utero exposures are of
most interest in relation to DNA methylation programming.
Conclusion
Based on an EWAS of relatively low levels of prenatal lead expo-
sure and DNA methylation in a prospective prebirth cohort, we
identified several CpGs of biological relevance for effects of
in utero exposure to lead. There were sex-specific differences in
the top CpGs associated with prenatal lead exposure, suggesting
a potential susceptibility difference in relation to lead exposure
between males and females. Further studies are needed to repli-
cate our findings and to investigate their relevance to specific
adverse health outcomes. Pending further investigation, our
results suggest that prenatal lead exposure, even at very low lev-
els, may modify the DNA methylation profiles in offspring, pro-
viding a mechanistic explanation for previously reported adverse
postpartum health outcomes of prenatal lead exposure.
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